Funding Announcements

"We are thrilled to partner with BGF and leverage their expertise and resources to take Kubus to the next level. As a business based in the heart of the Cotswolds, we’re proud to be working with businesses and organisations across the world. This investment will allow us to accelerate our global growth plans, innovate faster, and deliver even greater value to our customers. With the added support of Paul Brennan in his new role as non-executive chair, the road ahead looks very exciting indeed."

"Today’s announcement marks a pivotal moment in Evolve’s journey. The investment from BGF is not just a testament to our robust growth and the confidence of our investors, it’s also a strategic step forward in advancing our mission to innovate in our industry, and take the pain out of connectivity for our customers. We are excited about the opportunities this investment will unlock and remain committed to delivering unparalleled value to our stakeholders."

"Switchee has been doubling year on year for the last three consecutive years. We are really proud of the Switchee journey, and the ethics and values we have built in the business are critical to us. We have had some great investor partnerships over the years and are thrilled to see AXA IM Alts further invest in us, and warmly welcome Octopus Ventures as a new investor. It is a sign of their trust in the team’s ability to execute our strategy; and we also see it as a stamp of approval in terms of the impact we are looking to achieve."

"It's a really exciting time for us. We're absolutely thrilled to have the trust and backing of our investors to solve what is a major crisis – millions of people are not in the workforce or falling out of it entirely. We've seen high employee turnover, in some instances up to 300% and the demand for workers has never been greater. Our technology powers organisations to improve engagement of these individuals by deeply understanding their needs and enabling them to receive better support, resulting in more people accessing and sustaining work,"

"Developing a drug remains an expensive and time-consuming process. Unlike other industries, product development in pharmaceuticals relies heavily on numerous experiments with minimal knowledge transfer from past products, driven by the expertise and know-how of scientists. We have witnessed first-hand the inefficiencies of traditional drug development, as well as the growing desire and business need to transform this field. Our vision for PolyModels Hub is to revolutionise how scientists, digital teams, and senior stakeholders collaborate to accelerate development efforts and bring breakthrough therapies to market faster than ever. With today’s advanced technology, supportive business context, and favourable regulatory framework, we believe now is the perfect time to realise this vision."